RecruitingPhase 2NCT05249959
Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.
Studying Mantle cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fondazione Italiana Linfomi - ETS
- Principal Investigator
- Marco LadettoS.C. Ematologia - A.S.O. "SS Antonio e Biagio e Cesare Arrigo" di Alessandria
- Intervention
- Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C))(drug)
- Enrollment
- 49 target
- Eligibility
- 18-79 years · All sexes
- Timeline
- 2022 – 2029
Study locations (21)
- ASST Spedali Civili di Brescia, Brescia, Italy, Italy
- S.C. Ematologia - A.S.O. "SS Antonio e Biagio e Cesare Arrigo", Alessandria, Italy
- S.C. di Ematologia - A.O. S. Croce e Carle, Cuneo, Italy
- Unità funzionale di Ematologia - Azienda Ospedaliera Universitaria Careggi, Florence, Italy
- Ematologia - Ospedale Policlinico San Martino S.S.R.L. - IRCCS per l'Oncologia, Genova, Italy
- Ematologia - Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
- S.C. Ematologia - ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
- UOC Ematologia Oncologica - Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale, Naples, Italy
- SCDU Ematologia - AOU Maggiore della Carità di Novara, Novara, Italy
- Divisione di Ematologia - A.O. Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy
- Divisione di Ematologia - IRCCS Policlinico S. Matteo di Pavia, Pavia, Italy
- Ematologia - Ospedale delle Croci, Ravenna, Italy
- Ematologia - Azienda Unitа Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
- U.O. di Ematologia - Ospedale degli Infermi di Rimini, Rimini, Italy
- Dipartimento di Medicina Traslazionale e di Precisione - Policlinico Umberto I - Università "La Sapienza" Istituto Ematologia, Roma, Italy
- +6 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05249959 on ClinicalTrials.govOther trials for Mantle cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07377578A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.
- RECRUITINGPHASE2NCT07272499Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseRuijin Hospital
- RECRUITINGPHASE2NCT07029737A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in SpainAstraZeneca
- RECRUITINGNANCT07257510Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell LymphomaPeking University Third Hospital
- RECRUITINGPHASE2NCT06846489Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell LymphomaSun Yat-sen University
- RECRUITINGPHASE3NCT06742996A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)BeOne Medicines
- RECRUITINGNCT06788652A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing SettingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
- RECRUITINGPHASE2NCT06522386GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell LymphomaM.D. Anderson Cancer Center